US President Trump’s latest salvo has, among other things, the threat to impose a 200% tariff on pharma imports. But it will be imposed only after a year. So, how seriously should Indian pharma companies, for whom the US is a significant market, take the latest threat?Logically, with a pinch of salt. For two key reasons.One, it is well known that if pharma products currently being made in India were to be manufactured in the US, it will cost six
